Enzyme Activities in Human Liver

2015 ◽  
pp. 67-129
Author(s):  
E. Schmidt ◽  
F. W. Schmidt
Xenobiotica ◽  
2016 ◽  
Vol 47 (4) ◽  
pp. 324-331 ◽  
Author(s):  
Michaela Kopečná-Zapletalová ◽  
Kristýna Krasulová ◽  
Pavel Anzenbacher ◽  
Petr Hodek ◽  
Eva Anzenbacherová

Molecules ◽  
2017 ◽  
Vol 22 (3) ◽  
pp. 443 ◽  
Author(s):  
Ju-Hyun Kim ◽  
Soon-Sang Kwon ◽  
Tae Kong ◽  
Jae Cheong ◽  
Hee Kim ◽  
...  

2003 ◽  
Vol 24 (9) ◽  
pp. 375-384 ◽  
Author(s):  
Anima Ghosal ◽  
Neil Hapangama ◽  
Yuan Yuan ◽  
Xiaowen Lu ◽  
Debra Horne ◽  
...  

1970 ◽  
Vol 11 (1-2) ◽  
pp. 67-129 ◽  
Author(s):  
E. Schmidt ◽  
F.W. Schmidt

Pharmaceutics ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 220
Author(s):  
Won-Gu Choi ◽  
Ria Park ◽  
Dong Kyun Kim ◽  
Yongho Shin ◽  
Yong-Yeon Cho ◽  
...  

Mertansine, a tubulin inhibitor, is used as the cytotoxic component of antibody–drug conjugates (ADCs) for cancer therapy. The effects of mertansine on uridine 5′-diphospho-glucuronosyltransferase (UGT) activities in human liver microsomes and its effects on the mRNA expression of cytochrome P450s (CYPs) and UGTs in human hepatocytes were evaluated to assess the potential for drug–drug interactions (DDIs). Mertansine potently inhibited UGT1A1-catalyzed SN-38 glucuronidation, UGT1A3-catalyzed chenodeoxycholic acid 24-acyl-β-glucuronidation, and UGT1A4-catalyzed trifluoperazine N-β-d-glucuronidation, with Ki values of 13.5 µM, 4.3 µM, and 21.2 µM, respectively, but no inhibition of UGT1A6, UGT1A9, and UGT2B7 enzyme activities was observed in human liver microsomes. A 48 h treatment of mertansine (1.25–2500 nM) in human hepatocytes resulted in the dose-dependent suppression of mRNA levels of CYP1A2, CYP2B6, CYP3A4, CYP2C8, CYP2C9, CYP2C19, UGT1A1, and UGT1A9, with IC50 values of 93.7 ± 109.1, 36.8 ± 18.3, 160.6 ± 167.4, 32.1 ± 14.9, 578.4 ± 452.0, 539.5 ± 233.4, 856.7 ± 781.9, and 54.1 ± 29.1 nM, respectively, and decreased the activities of CYP1A2-mediated phenacetin O-deethylase, CYP2B6-mediated bupropion hydroxylase, and CYP3A4-mediated midazolam 1′-hydroxylase. These in vitro DDI potentials of mertansine with CYP1A2, CYP2B6, CYP2C8/9/19, CYP3A4, UGT1A1, and UGT1A9 substrates suggest that it is necessary to carefully characterize the DDI potentials of ADC candidates with mertansine as a payload in the clinic.


1977 ◽  
Vol 52 (3) ◽  
pp. 229-239 ◽  
Author(s):  
Carol A. Seymour ◽  
T. J. Peters

1. Highly sensitive techniques are described for the assay of plasma membrane (5′-nucleotidase, alkaline phosphatase), microsomal (neutral α-glucosidase, leucyl-2-naphthylamidase) and biliary canalicular (γ-glutamyltransferase) enzymes and for nine acid hydrolases (acid phosphatase, phosphodiesterase, β-glucosidase, α-glucosidase, α-galactosidase, β-galactosidase, α-mannosidase, N-acetyl-β-glucosaminidase, β-glucuronidase) in human liver. 2. Optimum and specific assay systems have been developed which give linear kinetics for all enzymes. 3. The range of enzyme activities in samples of human liver, obtained by closed needle biopsy, and in sera have been determined.


Sign in / Sign up

Export Citation Format

Share Document